Alkermes (ALKS) Assets Average (2011 - 2026)
Alkermes' (ALKS) quarterly Assets Average came in at $4.3 billion in Q2 2026, up 99.58% year-over-year from $2.2 billion in Q2 2025, and up 28.26% quarter-over-quarter from $3.4 billion in Q1 2026.
Analysis
Alkermes (ALKS) Assets Average (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Assets Average for 16 consecutive years, with $4.3 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Assets Average rose 99.58% year-over-year to $4.3 billion in Q2 2026; TTM through Jun 2026 was $4.3 billion, a 99.58% increase from a year earlier, with the FY2025 full-year figure at $2.3 billion, up 8.37% from the prior year.
- Assets Average was $4.3 billion for Q2 2026 at Alkermes, up from $3.4 billion in the prior quarter.
- Over five years, Assets Average peaked at $4.3 billion in Q2 2026 and troughed at $1.9 billion in Q1 2023.
- A 5-year average of $2.3 billion and a median of $2.1 billion in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average decreased 4.63% in 2024 and surged 99.58% in 2026, its largest moves.
- Over 5 years, Assets Average stood at $2.0 billion in 2022, then gained by 13.05% to $2.2 billion in 2023, then declined by 4.63% to $2.1 billion in 2024, then increased by 14.38% to $2.4 billion in 2025, then jumped by 79.62% to $4.3 billion in 2026.
- The last three Assets Average figures came in at $4.3 billion (Q2 2026), $3.4 billion (Q1 2026), and $2.4 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 120.28 Bn |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | 204.57 Bn |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | 149.95 Bn |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | 3.29 Bn |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | 7.61 Bn |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | 6.97 Bn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | 4.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.33 Bn |
| Mar 31, 2026 | 3.37 Bn |
| Dec 31, 2025 | 2.41 Bn |
| Sep 30, 2025 | 2.29 Bn |
| Jun 30, 2025 | 2.17 Bn |
| Mar 31, 2025 | 2.07 Bn |
| Dec 31, 2024 | 2.11 Bn |
| Sep 30, 2024 | 2.18 Bn |
| Jun 30, 2024 | 2.17 Bn |
| Mar 31, 2024 | 2.13 Bn |
| Dec 31, 2023 | 2.21 Bn |
| Sep 30, 2023 | 2.23 Bn |
| Jun 30, 2023 | 2.05 Bn |
| Mar 31, 2023 | 1.94 Bn |
| Dec 31, 2022 | 1.95 Bn |
| Sep 30, 2022 | 1.95 Bn |
| Jun 30, 2022 | 1.97 Bn |
| Mar 31, 2022 | 2.00 Bn |
| Dec 31, 2021 | 2.01 Bn |
| Sep 30, 2021 | 1.97 Bn |